Heroin is one of the major target drugs in workplace drug-testing programs because of its history of abuse, liability, and continued negative social impact. This study was a comprehensive examination of pharmacokinetics, pharmacodynamics, detection times, opiate immunoassay performance, and urine excretion profiles following single doses of heroin administered to human subjects via smoking and intravenous routes. Studies of the first four components of this investigation were previously published. This article describes the urine excretion profiles. Total morphine (Tmor), free morphine (Fmor), and 6-acetylmorphine (6-AM) were measured by gas chromatography-mass spectrometry (GC-MS) in 920 urine samples collected from 11 male human subjects following single doses of heroin. Eight received intravenous doses of 3, 6, and 12 mg heroin HCI and four smoked 3.5-, 5.2-, 7-, 10.5-, or 13.9-mg doses of heroin (base). In addition, 183 urinebased blind quality-control samples were added to the study set to assess assay performance. Creatinine was also measured in each sample by a colorimetric technique. The parameters studied were not significantly dependent on route of administration. Excretion half-life mean _+ SD for Tmor was 3.11 _+ 0.30 h. Range (median) of peak urine concentrations, time to peak, time to last positive sample for low cutoff (300 ng/mL) and high cutoff (2000 ng/mL) for Tmor following lower doses (_< 7 rag) were, respectively, 1392-9250 (3620) ng/mL, 1.2-6.2 (2.3) h, 7.4-31.9 (7.4) h, and 0-10.1 (4.3) h. Following higher doses (> 10 rag) they were 2065-29,030 (16,470) ng/mL, 2.3-9.3 (4.5) h, 10.7-53.5 (34.4) h, 2.3-22.3 (8.3) h. Fmor peaked in the same sample as Tmor. Range (median) of peak Fmor concentrations and time to last positive using a cutoff of 100 ng/m/for low and high doses were,
Introduction
Heroin was first synthesized from morphine in 1874 and is listed by the Drug Enforcement Administration as a Schedule I substance (having no current medical use) under the Controlled Substances Act of 1970 (1) . It is a highly addictive drug of abuse, and the National Drug Intelligence Center estimates the number of hard-core users in the United States is 980,000 with the number of total users between 1.2 and 1.5 million (2) . Even though prevalence in most workplace programs is low (e.g., < 0.001% in the Department of Defense [DOD] ), heroin remains one of the selected drugs in testing panels because of its history of abuse, high abuse liability, risk of morbidity, and need to prevent workplace use. One significant historical event that impacted policy makers and resulted in heroin use being monitored in drug-testing programs was the return of service members from Vietnam and reports that -42% had used heroin and about half of these individuals were addicted to heroin at some time (3) . Studies from the Vietnam era confirm the high abuse liability of this drug (1) . The negative acute and chronic health effects of heroin, such as respiratory depression, contributed to 4820 deaths in 1999 according to the Drug Abuse Warning Network (DAWN) (4) . Monitoring within the United States has shown that the prevalence of heroin use is regional. For example, in 1999, the percentage of adult male arrestees with an opiatepositive urinalysis in New York City was 15.2%, compared with 4.3% in Atlanta (5) . The most common route of administration was the intravenous route, but preference for the smoking route was also prevalent in a number of regions, and this latter group had a lower incidence of HIV infection (6) . Other facts that support continued monitoring for heroin use in drug deterrence programs and increase the need for additional scientific studies include heroin use increased substantially from 1992 to 1997; simultaneous use of heroin and cocaine resulted in a significant increase in emergency room visits in 1998; heroin (ranking third in DAWN data) accounted for 15% of emergency room visits in 1999; and abuse of heroin included younger populations with the percent of eighth graders reporting prior use increasing from 1.4% in 1992 to 2.3% in 1999 (2) .
To better understand heroin abuse scientists conducted clinical trials focusing on pharmacokinetics and pharmacodynamics (7) (8) (9) (10) . These studies demonstrated that heroin disappeared from blood rapidly, with half-lives (tl~o) of approximately 3 rain, to form 6-acetylmorphine (6-AM) ~hich further metabolized with tl~o -5 rain to free morphine (Fmor) and conjugated morphine, primarily morphine-3-glucuronide, and morphine-6-glucuronide in adult humans. Fmor was eliminated from blood with t~/2 -18 min. In some of these studies, the quantity total morphine (Tmor), which was the combination of Fmor and conjugated morphine metabolites, was used because it was very difficult to directly measure the morphine glucuronide conjugates. Intramuscular and intranasal routes of administration differed in relative potency but other pharmacokinetic profiles and pharmacodynamic effects were similar. Pharmacodynamic components of these studies showed that with most doses of 6 mg or greater and for most routes of administration subjects demonstrated pupil constriction, decrease in respiration, a slight rise in temperature, increase in euphoria, sedation, dysphoria, and elevated subjective scores of "drug liking" and "feel drug". Gyr et al. (10) studied much higher doses of heroin, 200-690 mg, in two dependent patients by the intravenous, oral, and rectal routes of administration. They reported increased pharmacodynamic effects, heroin half-lives of 1.3-2.2 rain, and morphine-3-glucuronide as the principal blood metabolite.
Both prior to and following these studies scientists also studied the excretion of heroin and its metabolites in urine. Measurements in urine were easier than those in blood and concentrations were generally higher. The advent of urine drug testing to monitor heroin use in the workplace, pre-employment, parole, and pretrial programs, as well as in medical examiner death investigations, increased the need for more data on excretion profiles. Some urine data were produced and published as early as 1936 when Shen et al. (11) found morphine in the urine of heroin users. Heroin was originally believed to be absent from urine, but subsequent studies demonstrated that this was not true. Elliott et al. (12) reported that following administration of 70 _ 5 mg of heroin intravenously over 7 h to four volunteers, urine contained up to 0.13% of the dose as heroin, 43% as Tmor, and 1.3% as 6-AM. Recent studies demonstrated that urine Tmor concentrations peaked at about 3-4 h after intramuscular injection of 6-rag doses of heroin and peak urine values ranged from 3316 to 12,022 ng/mL. The majority of 6-AM was excreted in the first urine void and had peak concentrations of 50 to 236 ng/mL (13, 14) . Following single oral doses of 10 mg heroin, time to peak for Tmor in urine was 2-9 h with peak concentrations of 4317-12,580 ng/mL and no 6-AM was excreted (15) . In most cases the principal urinary metabolite for adult humans, from a study of urine from heroin overdose victims, was morphine-3-glucuronide which ranged from 0.74 to 9.2 times and 1.8 to 25 times that of morphine-6-glucuronide and Fmor, respectively (16) . In other studies of heroin administered both intranasally and intramuscularly, Fmor and Tmor in urine each had peak concentrations in the same urine void, and Fmor ranged from 4 to 24% of the Tmor concentration (14, 17) .
Although the previous excretion studies contributed to a general understanding of heroin metabolism, detailed studies of metabolite concentrations following single doses by the most common routes of administration, smoking and intravenous, were lacking. This became a very important deficit for officials in urine drug-testing programs who had to make policy decisions or interpret urinalysis results. Establishing appropriate cutoff concentrations was difficult and became more complicated following published studies showing that morphine was excreted by individuals who ingested poppy seeds, a very common foodstuff. This meant that these individuals could be falsely accused of heroin use if only Tmor were used as an indicator. Therefore, the DOD (1994) and Department of Health and Human Services (HHS, 1998) raised Tmor cutoff concentrations, from 300 to 2000 ng/mL, and mandated testing for the heroin associated metabolite 6-AM (cutoff concentration 10 ng/mL) to better address this problem. The present study was undertaken to describe the metabolism of heroin following single doses by the smoking and intravenous routes of administration. Pharmacokinetics and pharmacodynamic results were previously published (9) . Results of screening urine specimens with opiate immunoassays that are commonly used by regulated and unregulated urine drugtesting programs were also published (18) . Detection times using a screening cutoff concentration of 300 ng/mL were 12 h and 24-48 h for low (~ 7 mg) and higher dose (> 10 mg) groups, respectively. Some low-dose users were missed when a 2000-ng/mL screening cutoff concentration was applied, and the detection time for the higher dose group was about 12 h. Despite missing more users the 2000-ng/mL cutoff concentration was more consistent with a 10-ng/mL confirmation cutoff concentration for 6-AM and assay efficiencies increased to over 97%. In this paper we describe the Tmor, Fmor, and 6-AM concentrations in urine for 72 h following single doses of heroin by the two common routes of administration.
Experimental Chemicals
Heroin hydrochloride used for intravenous administration was obtained from the Research Technology Branch, National Institute on Drug Abuse (Rockville, MD). Heroin (base) used in smoking experiments was produced by neutralization of the heroin hydrochloride with base followed by purification. 6-AM hydrochloride, morphine-d> 6-AM-d6 hydrochloride, and morphine were obtained from Research Triangle Institute (Research Triangle Park, NC) and used in analytical procedures. All solvents and reagents were of high-performance liquid chromatography (HPLC)-grade quality.
Subjects
Twelve healthy male volunteer subjects with a history of heroin abuse gave informed consent and participated in the study. Before entering the study, each subject was required to test negative in urine for three consecutive days by Abuscreen | radioimmunoassay or EMIT ~ immunoassay for morphine (300-ng/mL cutoff concentration). The study was conducted on a medically supervised, closed clinical ward at the Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health (Bayview Campus, Baltimore, MD) under the guidelines for the protection of human subjects. Subjects received doses of drug between 8 and 10 a.m. Some of the subjects participated in more than one dosing regimen with at least three days between sessions.
Dosing
Four subjects received single doses of heroin (base) via smoking. Some subjects participated in more than one dosing session. The uniform delivery device and smoking procedures were described previously (9) . The doses inhaled in milligrams (number of subjects) were 0 (1), 3.5 (4), 5.2 (1), 7 (2), 10.5 (2), and 13.9 (1). Doses of 5.2 and 10.5 mg free base heroin are similar to the doses of 6 and 12 mg of heroin hydrochloride used for intravenous administration.
Eight subjects received single intravenous doses of heroin hydrochloride in the order 3, 6, then 12 mg with three days between doses. One subject also received placebo (saline) four days before receiving any heroin. At least one urine sample was collected prior to dosing. Following dosing each urine voided over a three-day period was collected and stored as an individual sample for testing.
Blind control preparation
Drug-free urine was fortified with different known amounts of morphine (25-1000 ng/mL), codeine (25-1000 ng/mL), 6-AM (1-100 ng/mL), morphine-3-glucuronide (300-6000 ng/mL), and morphine-6-glucuronide (500-6000 ng/mL). Also, standards of hydromorphone, hydrocodone, oxycodone, oxymorphone, methadone, norcodeine, and normorphine were each prepared in urine at a concentration of 300 ng/mL. Combinations of standards were prepared containing 300 ng/mL of morphine and one of the following drugs each at i mg/mL in order to study potential interferences: salicylic acid, caffeine, diphenhydramine, cocaine, acetylsalicylic acid, pseudoephedrine, ephedrine, dextromethorphan, doxylamine, chlorpheniramine, and brompheniramine. A similar blind sample was made with 0.5 mg/mL of phenobarbital. Each level of drug standard or control was prepared in triplicate. The number of fortified specimens together with drug-free urine specimens and the specimens obtained from the subjects who received heroin was 1103.
Assays
All assays were performed on freshly thawed specimens. The specimens were assayed in random order under blind conditions. Results were decoded only after completion of the assay. Assay by gas chromatography-mass spectrometry (GC-MS) was performed according to published procedures for Tmor, Fmor, and 6-AM (19) . Briefly, analytes and deuterated internal standards were isolated by solid-phase extraction, derivatized with propionic anhydride, and quantitated using a Hewlett Packard 5890 series II Plus GC-5972 quadrupole mass selective detector operated in the selected ion monitoring mode. Acid hydrolysis was used in the assay for Tmor. For hydrolysis, 0.5 mL of 11.6M HCI was added to 5 mL of urine. The solution was heated at 121~ (15 psi) for 15 rain. The solution was cooled to room temperature and adjusted to pH 5.5-6.0. Morphine was isolated using solid-phase extraction. Morphine and 6-AM limits of detection were 5 and 3 ng/mL, respectively. Measurement of 6-AM at concentrations below 3 ng/mL is subject to interference from high concentrations of morphine with this procedure because the propionic anhydride contains trace amounts of acetic anhydride impurity. If 6-AM was present but below 3 ng/mL, a sample aliquot was reprocessed using pentafluoropropionic anhydride derivatizing reagent with a limit of detection of 0.5 ng/mL. Urine-based controls were prepared containing morphine, morphine-3-glucuronide, or 6-AM at one-half cutoff concentration and twice the cutoff concentration. Controls for all GC-MS testing were stored frozen at -18~ with the specimens for testing prior to beginning sample analysis. Frozen controls were removed, thawed, and assayed with the specimens. For an assay to be acceptable, all controls had to give an acceptable GC-MS result with concentration + 20% of expected value.
Creatinine was measured in each sample using a commercial picric acid method adapted for an Olympus AU-800 analyzer (Chimera Research and Chemical, Inc., Asheville, NC). Controls contained 5, 25, and 104 mg/dL of creatinine in synthetic urine. Each analytical run was acceptable if all controls were • 20% of expected value.
Specimen collection, storage, and testing time
Urine specimens were collected during the period of February 5, 1993-July 5, 1994, in plastic bottles and frozen immediately at -30~ Blind quality-control samples were incorporated into the specimen batch in July 1996 and all samples were transferred from the clinical site to the test site and stored at -18~ GC-MS assays were conducted during the period of January 1997-February 1998.
Stability study
Drug-free urine was spiked with either morphine at 8000 ng/mL or 6-AM at 20 ng/mL. Aliquots of each pool were made. Four aliquots of each pool were selected and tested by GC-MS. The remaining aliquots were stored at either room temperature, 3 to 6~ or -15 to -18~ for 21 months. Four aliquots in each of the storage groups were removed and analyzed by the same GC-MS method.
Calculations
Half-lives were calculated by plotting the natural logarithm of concentration of analyte against time after peak concentration and computing the slope. The plots were truncated when data points deviated more than 20% from an expected linear value. The half-life was computed by dividing 0.693 by the slope.
Journat of Analytical Toxicology, Vol. 25, October 2OO1 Tables I and II show results for Tmor, Fmor, 6-AM, and creatinine concentrations in each urine sample collected after a single dose of heroin. There were no significant differences in concentration profiles between the intravenous and smoking route of administration. Some of the doses given for each route were similar, but not identical. The intravenous drug was the hydrochloride salt that contained 91% of the same mass of heroin base administered in the smoking trials. This meant that the 6-and 12-rag intravenous doses of heroin hydrochloride were similar to the 5.2-and 10.5-rag smoked doses of heroin base. A special smoking device and smoking regimen were used to minimize drug losses, and these procedures were described in an earlier publication (9). Concentrations of metabolites did differ with dose and were evaluated by considering the doses as a lower (3--7 rag) and a higher (10.5-13.9 mg) dose group. The time from dosing to peak urine concentration of the metabolites studied ranged from 1.2 to 6.2 h with a median of 2.4 h for the lower dose group and 2.3 to 9.3 h with a median 0  155  131  1307  47  0  320  61  484  19  0  238  57  304  13  0  245  92  324  0  0  255  76  139  0  0  145  91  55  0  0  235  57  16  0  0  180  110  20  0  0  180  89  10  0  0  145  88  8  0  0  110  133  0  0  0  120  114  0  0  0   130  159  0  0  260  156  5645  512  170  165  3700  228  195  117  1551  50  210  123  1341  51  205  103  714  16  105  112  606  26  275  85  239  12  255  82  237  0  155  101  214  7  265  89  155  5  130  73  88  0  275  89  65  0  280  119  59  0  245  72  22  0  240  131  28  0  225  139  24  0  120  137  15  0  185  190  21  0  100 of 4.5 h for the higher dose group. For all of the lower doses and some of the higher doses, the peak concentration occurred in the first urine void. Urine samples were collected whenever subjects needed to urinate, and this variation in time was a major determinant of the time to peak concentration. As can be seen in Tables I and II, some subjects receiving higher doses had a peak concentration of analyte in the second urine collected and one had peak Trnor in the third.
Results and Discussion
The excretion half-lives for Tmor were not significantly different between the doses in this study. Values were generally higher at the higher doses for a particular individual, but these differences were not statistically, or practically, different. The 0  80  858  42  0  74  666  30  0  38  349  18  0  46  439  0  0  27  219  9  0  31  258  0  0  36  287  0  0  75  492  17  0  40  234  0  0  52  196  7  0  64  282  8  0  25  98  0  0  37  125  0  0  42  143  4  0  85  302  0  0  61  173  0  0  131  264  11  0  99  167  0  0  75  103  5  0  69  86  0  0  86  104  0  0  49  44  0  0  80  53  0  0  50  30  0  0  28 from 7.4 to 31.9 (15.7) h. For the higher dose group, the range (median) was 10.7-53.5 (34.4) h. One interpretation of these results is that programs using a 300-ng/mL cutoff concentration for Tmor in a heroin detection program would expect to identify most users for 1/2 day and 11/2 days following low (3-7 rag) and high (10.5-13.9 rag) single doses, respectively. Programs that use a 2000-ng/mL cutoff concentration for Tmor, such as DOD-and HHS-regulated programs, would expect to identify heroin users with this criterion for 0-10.1 (4.3) h and 2. 3-22.3 (8. 3) h following lower and higher single doses of heroin. Note that the zero hour detection time means that this individual would not be detected. The 2000 ng/mL Tmor concentration was exceeded in all but 2 of the 23 low-dose sessions. Both the regulated programs mentioned also require that 6-AM be measured in samples that are positive for Tmor. The sample is designated as positive for 6-AM, a specific heroin metabolite, if the concentration is > 10 ng/mL. In this study several subjects receiving the lower doses did not produce any samples with a positive 6-AM and the majority of the remaining subjects were negative after the first void. Subjects receiving the higher dose were negative after 12 h. Raising the administrative cutoff concentration for Tmor to 2000 ng/mL and re- 100-ng/mL cutoff Fmor 10-ng/mL cutoff 6-AM quiring 6-AM to be present at > 10 ng/mL significantly reduced the detection time for heroin use. However, these two cutoff concentrations were consistent and, when combined with immunoassays to identify heroin users, increased the efficiency of testing to over 97% (18) . Some investigators have suggested that drug testing programs could measure Fmor and use a 100 ng/mL cutoff concentration (19) . This would allow measurement of morphine and 6-AM by the laboratory in the same confirmation extract saving analyst time and reducing sample handling errors. Ranges (medians) to last positive sample using this recommended cutoff concentration were 1.2-10.1 (4.5) h and 2.3-29.1 (9.3) h for the lower and higher dose subjects. These detection times are also in concordance with the 10-ng/mL 6-AM cutoff concentration. Drug rehabilitation and parole programs monitor individual drug use over time instead of trying to identify unknown users. In these programs it is important to identify new drug use by an individual who may have had a previous positive urine sample. Methods for accomplishing this have been reported for marijuana and opiates (20, 21) . Often, continued drug use would have severe consequences, for example, a return to confinement for a parolee or loss of a job for an employee in a rehabilitation program. The principal problem in identifying new use is apparent from the representative excretion profile shown in Figure 1 . Figure I shows the urine concentrations of Tmor in samples collected from Subject G beginning at 9 h after re- time frame 9 h post-dosing is shown for in-6.1-298 structive purposes. The subject had a negative sample (300-ng/mL cutoff concentra-
tion) collected at 12 h followed by seven positive samples, then another negative sample at 35 h followed by four more positive samples until all samples became negative after 44 h. This phenomenon is well known and demonstrates why one cannot use the occurrence of a positive specimen 04.1 following a negative specimen to identify (2.3) new drug use (22) . One recommended solution is to report results for individuals in 1. 4-4.3 drug use monitoring programs as ng (2.4) drug/mg creatinine because much of the variability in drug concentration is due to (242) physiological sample dilution. Creatinine is generally thought to be excreted at a constant rate (20) . Figure 1 shows that expressing results this way smoothes the excretion plot. Expressing results as 100*ng drug excretion and elevate the probability (4.5) that an increased value would represent new drug use.
The range (median) percent of total dose of drug excreted for all subjects in all trials was 12.8--88.5% (51.0). This large range demonstrates the variability of individuals in metabolizing and excreting heroin. The variability occurred within and between subjects. For example, one individual ranged from 12.8 to 22.2% and another from 16.8 to 50.6%. Efforts were made to ensure uniformity of smoking doses but the range of drug excreted was still large as was the range for intravenous administration where subjects were assumed to receive the full dose administered. A large range in percent of drug excreted, 42-67.2% (57), was also observed in previous studies by the intramuscular route of administration (13) .
Because concentrations of analytes were important in this study, we conducted a number of validity tests on the GC-MS assay and specimen measurements. Initially, limits of detection, intra-and interassay coefficients of variation, and linear range were determined and published (19) . Current methods were improvements of previous assays (23, 24) . We also analyzed 183 urine-based blind proficiency samples. These samples contained morphine, 6-AM, or morphine mixed with a number of potentially interfering substances and were stored frozen with specimens for two years. None of the interfering substances prevented a valid analytical measurement or yielded a false-positive result. Measured values of the analytes were compared to the expected values. The concentration range and intercept/slope (R 2) were 25-1000 ng/mL, -3.81/1.13 (0.9998) for Tmor; 25-1000 ng/mL, --4.94/1.04 (1.0000) for Fmor; and 2.5-100 ng/mL, 0.27/0.91 (1.0000) for 6-AM, respectively. Because specimens were stored frozen for two and one half to five years prior to GC-MS analysis we also conducted a stability study as described in the experimental section. Urine based samples containing morphine and 6-AM were stored at room temperature, 3-6~ and -15 to -18~ for over one year. Morphine mean recoveries + SEM were 95 • 0.3%, 100 • 0.5% and 102 • 0.2%, respectively. This agreed with previously reported Time (h) studies (25) . 6-AM recoveries were 12 + 1%, 21 • 0.6%, and 106
• 0.8%, respectively, demonstrating stability in the frozen state for over one year. In addition, the morphine, morphine glucuronide, and 6-AM controls that were stored frozen for up to 21 months then thawed and analyzed during confirmation testing were all within _+ 20% of expected values. Based on the stability study and results from control solutions, all analytes showed no significant degradation when stored at-18~ for up to 21 months. The stability studies did not directly parallel the specimens that were stored at -30~ for two and one half to five years before analysis. The study did, however, show some measure of long term stability of analytes in the frozen state. Each subject in this study received placebo and then urine samples were collected for 72 h. Samples were analyzed from one subject receiving placebo intravenously and one receiving a smoked placebo and none of the urine samples collected contained any heroin metabolites above the limit of detection.
Conclusions
Eight male human subjects received single intravenous doses of 3, 6, and 12 mg of heroin HCl and four smoked single doses of 3.5, 5.2, 7, 10.5, and 13.9 mg of heroin base. Every urine sample was collected from each subject for about 72 h following dosing and the Tmor, Fmor, and 6-AM concentrations were measured by GC-MS. Excretion half-life mean + SD for Tmor was 3.11 + 0.30 h. The route of administration did not significantly affect the parameters measured, so all subjects were divided by dose into a lower dose (3-7 mg) and a higher dose (10.5-13.9 rag) group. The range (median) of peak urine concentrations, time to peak, and time to last positive sample for low cutoff concentration (300 ng/mL) and high cutoff concentration (2000 ng/mL) for Tmor following lower doses (5 7 rag) were 1392-9250 (3620) ng/mL, 1. .3) h. Fmor peaked in the same sample as Tmor. Range (median) of peak Fmor concentrations and time to last positive using a cutoff concentration of 100 ng/mL for low and high doses were 117-1160 (415) ng/mL, 1.2-10.1 (4.5) h and 150-2580 (1400) ng/mL, 2.3-29.1 (9.3) h, respectively. The range (median) of peak urine concentration for 6-AM were 6.1-568 (124) loo ng/mL. In general, the peak 6-AM concentration was in the first void and was the only positive sample using the 10-ng/mL cutoff concentration. As previously reported, urine concentrations varied greatly between subjects and within subjects with time after dosing, but were more predictable Figure 1 . Urine concentration of total morphine (Tmor) with time (after 9 h) following heroin administration for a representative human subject. Concentration expressed as ng/mL and l O0*ng/mg of creatinine demonstrating the smoothing effect of the latter units. Cutoff chosen for instructive purposes was 300 ng/mL.
when values were reported as amount of drug per unit of creatinine. The range (median) values for the amount of heroin excreted in urine as Tmor was 12.8--88.5% (51.0). This result demonstrated large intra-and intersubject variability in metabolism and excretion.
